Traders should monitor the webcast for any unexpected commentary on SAT-3247 clinical trials (BASECAMP/TRAILHEAD) or pipeline updates, but no material announcements are expected. Increased investor engagement could support sentiment ahead of future catalysts.
Price Chart
Executive Summary
Satellos Bioscience announced it will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026, where CEO Frank Gleeson will host a presentation and management will hold one-on-one meetings. This is a routine investor relations update with no new financial or clinical data disclosed.
Key Facts
- Satellos Bioscience (MSLE) will participate in the Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026.
- CEO Frank Gleeson will deliver a presentation on April 21 at 11:30 a.m. ET, and CFO Liz Williams will join one-on-one meetings.
- The presentation will be webcast and available on the company's website, but no new clinical or financial information will be released.
- This 6-K filing is solely to attach the press release announcing the conference participation.
Financial Impact
No immediate financial impact; presentation may improve investor visibility.
Risk Factors
- Low attendance or lack of follow-up interest from investors could limit the event's effectiveness.
- Failure to provide new data or guidance may result in minimal stock price movement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002337 |
| Exhibit: exh_991.htm | 0001171843-26-002337 |
| Document: 0001171843-26-002337-index-headers.html | 0001171843-26-002337 |
| Document: 0001171843-26-002337-index.html | 0001171843-26-002337 |
| Document: 0001171843-26-002337.txt | 0001171843-26-002337 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.98 (+8.70%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.98 (+4.16%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.98 (−13.31%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.98 (−17.90%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.98 (−17.90%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.98 (−19.88%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.98 (−19.88%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.98 (−25.44%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.98 (−30.36%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.98 (−23.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers